Evaluation of the lumipulse G TP-N chemiluminescent immunoassay as a syphilis screening test

Daniel A. Ortiz, Michael J. Loeffelholz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A syphilis diagnosis is often aided by the detection of treponemal and nontreponemal antibodies. Automated treponemal antibody detection systems enable high-volume clinical laboratories to perform syphilis screening at a faster pace with lower labor costs. The Lumipulse G TP-N chemiluminescent immunoassay is an automated system that qualitatively detects IgG and IgM antibodies against Treponema pallidum antigens in human serum and plasma. To assess performance characteristics and workflow efficiency, the Lumipulse G TP-N assay was compared to the Bioplex 2200 Syphilis IgG multiplex flow immunoassay. Among the 4,134 routine and HIV samples tested by the two automated assays, the percentage of agreement was excellent at 99.0% (95% confidence interval [CI], 98.6% to 99.2%;, 0.89), with the Lumipulse G TP-N having a shorter time to first and subsequent results. All specimens with reactive syphilis screening results were further tested by rapid plasma reagin (RPR) and Treponema pallidum particle agglutination (TPPA) testing (n 231). The results from the RPR-reactive samples (n 82) showed complete concordance with the two automated assays, while the TPPA assay displayed some discrepancies. The positive percent agreement (PPA) and negative percent agreement (NPA) between the TPPA test and the Lumipulse G TP-N test were 98.9% and 77.3%, respectively. The Bioplex 2200 Syphilis IgG immunoassay displayed a similar PPA (100%) but a substantially lower NPA (15.9%). Patient chart reviews of discrepant results suggested that the Lumipulse G TP-N assay produced 27 fewer falsely reactive results and can reduce the amount of additional confirmatory RPR and TPPA testing needed. The analogous performance characteristics of the two automated systems indicate that the Lumipulse G TP-N assay is suitable for high-throughput syphilis screening.

Original languageEnglish (US)
Pages (from-to)3236-3241
Number of pages6
JournalJournal of Clinical Microbiology
Volume55
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Treponema pallidum
Syphilis
Immunoassay
Reagins
Agglutination
Immunoglobulin G
Antibodies
Agglutination Tests
Workflow
Immunoglobulin M
HIV
Confidence Intervals
Antigens
Costs and Cost Analysis
Serum

Keywords

  • Chemiluminescent enzyme immunoassay
  • Lumipulse G TP-N
  • Syphilis
  • Treponemal test

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Evaluation of the lumipulse G TP-N chemiluminescent immunoassay as a syphilis screening test. / Ortiz, Daniel A.; Loeffelholz, Michael J.

In: Journal of Clinical Microbiology, Vol. 55, No. 11, 01.11.2017, p. 3236-3241.

Research output: Contribution to journalArticle

Ortiz, Daniel A. ; Loeffelholz, Michael J. / Evaluation of the lumipulse G TP-N chemiluminescent immunoassay as a syphilis screening test. In: Journal of Clinical Microbiology. 2017 ; Vol. 55, No. 11. pp. 3236-3241.
@article{738739272fcb4c4f813440d2b4f832dc,
title = "Evaluation of the lumipulse G TP-N chemiluminescent immunoassay as a syphilis screening test",
abstract = "A syphilis diagnosis is often aided by the detection of treponemal and nontreponemal antibodies. Automated treponemal antibody detection systems enable high-volume clinical laboratories to perform syphilis screening at a faster pace with lower labor costs. The Lumipulse G TP-N chemiluminescent immunoassay is an automated system that qualitatively detects IgG and IgM antibodies against Treponema pallidum antigens in human serum and plasma. To assess performance characteristics and workflow efficiency, the Lumipulse G TP-N assay was compared to the Bioplex 2200 Syphilis IgG multiplex flow immunoassay. Among the 4,134 routine and HIV samples tested by the two automated assays, the percentage of agreement was excellent at 99.0{\%} (95{\%} confidence interval [CI], 98.6{\%} to 99.2{\%};, 0.89), with the Lumipulse G TP-N having a shorter time to first and subsequent results. All specimens with reactive syphilis screening results were further tested by rapid plasma reagin (RPR) and Treponema pallidum particle agglutination (TPPA) testing (n 231). The results from the RPR-reactive samples (n 82) showed complete concordance with the two automated assays, while the TPPA assay displayed some discrepancies. The positive percent agreement (PPA) and negative percent agreement (NPA) between the TPPA test and the Lumipulse G TP-N test were 98.9{\%} and 77.3{\%}, respectively. The Bioplex 2200 Syphilis IgG immunoassay displayed a similar PPA (100{\%}) but a substantially lower NPA (15.9{\%}). Patient chart reviews of discrepant results suggested that the Lumipulse G TP-N assay produced 27 fewer falsely reactive results and can reduce the amount of additional confirmatory RPR and TPPA testing needed. The analogous performance characteristics of the two automated systems indicate that the Lumipulse G TP-N assay is suitable for high-throughput syphilis screening.",
keywords = "Chemiluminescent enzyme immunoassay, Lumipulse G TP-N, Syphilis, Treponemal test",
author = "Ortiz, {Daniel A.} and Loeffelholz, {Michael J.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1128/JCM.00966-17",
language = "English (US)",
volume = "55",
pages = "3236--3241",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Evaluation of the lumipulse G TP-N chemiluminescent immunoassay as a syphilis screening test

AU - Ortiz, Daniel A.

AU - Loeffelholz, Michael J.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - A syphilis diagnosis is often aided by the detection of treponemal and nontreponemal antibodies. Automated treponemal antibody detection systems enable high-volume clinical laboratories to perform syphilis screening at a faster pace with lower labor costs. The Lumipulse G TP-N chemiluminescent immunoassay is an automated system that qualitatively detects IgG and IgM antibodies against Treponema pallidum antigens in human serum and plasma. To assess performance characteristics and workflow efficiency, the Lumipulse G TP-N assay was compared to the Bioplex 2200 Syphilis IgG multiplex flow immunoassay. Among the 4,134 routine and HIV samples tested by the two automated assays, the percentage of agreement was excellent at 99.0% (95% confidence interval [CI], 98.6% to 99.2%;, 0.89), with the Lumipulse G TP-N having a shorter time to first and subsequent results. All specimens with reactive syphilis screening results were further tested by rapid plasma reagin (RPR) and Treponema pallidum particle agglutination (TPPA) testing (n 231). The results from the RPR-reactive samples (n 82) showed complete concordance with the two automated assays, while the TPPA assay displayed some discrepancies. The positive percent agreement (PPA) and negative percent agreement (NPA) between the TPPA test and the Lumipulse G TP-N test were 98.9% and 77.3%, respectively. The Bioplex 2200 Syphilis IgG immunoassay displayed a similar PPA (100%) but a substantially lower NPA (15.9%). Patient chart reviews of discrepant results suggested that the Lumipulse G TP-N assay produced 27 fewer falsely reactive results and can reduce the amount of additional confirmatory RPR and TPPA testing needed. The analogous performance characteristics of the two automated systems indicate that the Lumipulse G TP-N assay is suitable for high-throughput syphilis screening.

AB - A syphilis diagnosis is often aided by the detection of treponemal and nontreponemal antibodies. Automated treponemal antibody detection systems enable high-volume clinical laboratories to perform syphilis screening at a faster pace with lower labor costs. The Lumipulse G TP-N chemiluminescent immunoassay is an automated system that qualitatively detects IgG and IgM antibodies against Treponema pallidum antigens in human serum and plasma. To assess performance characteristics and workflow efficiency, the Lumipulse G TP-N assay was compared to the Bioplex 2200 Syphilis IgG multiplex flow immunoassay. Among the 4,134 routine and HIV samples tested by the two automated assays, the percentage of agreement was excellent at 99.0% (95% confidence interval [CI], 98.6% to 99.2%;, 0.89), with the Lumipulse G TP-N having a shorter time to first and subsequent results. All specimens with reactive syphilis screening results were further tested by rapid plasma reagin (RPR) and Treponema pallidum particle agglutination (TPPA) testing (n 231). The results from the RPR-reactive samples (n 82) showed complete concordance with the two automated assays, while the TPPA assay displayed some discrepancies. The positive percent agreement (PPA) and negative percent agreement (NPA) between the TPPA test and the Lumipulse G TP-N test were 98.9% and 77.3%, respectively. The Bioplex 2200 Syphilis IgG immunoassay displayed a similar PPA (100%) but a substantially lower NPA (15.9%). Patient chart reviews of discrepant results suggested that the Lumipulse G TP-N assay produced 27 fewer falsely reactive results and can reduce the amount of additional confirmatory RPR and TPPA testing needed. The analogous performance characteristics of the two automated systems indicate that the Lumipulse G TP-N assay is suitable for high-throughput syphilis screening.

KW - Chemiluminescent enzyme immunoassay

KW - Lumipulse G TP-N

KW - Syphilis

KW - Treponemal test

UR - http://www.scopus.com/inward/record.url?scp=85032440967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032440967&partnerID=8YFLogxK

U2 - 10.1128/JCM.00966-17

DO - 10.1128/JCM.00966-17

M3 - Article

C2 - 28878003

AN - SCOPUS:85032440967

VL - 55

SP - 3236

EP - 3241

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 11

ER -